Radiopharmaceutical firm Ion Beam Applications (IBA) has inked an agreement with a South Korean firm to market PET radiopharmaceuticals in that country, according to the Louvain-la-Neuve, Belgium-based company.
IBA and radiation oncology and nuclear medicine products firm Hae Dong have signed a memorandum of understanding to educate nuclear medicine physicians in South Korea on the benefits of PET. Hae Dong will be IBA's preferred partner for the distribution of PET radiopharmaceuticals.
The addition of Hae Dong's seven FDG production centers (five operational and two under construction) in South Korea means that IBA's PET radiopharmaceutical production and distribution network now includes a total of 45 facilities worldwide, IBA said.
Copyright © 2008 AuntMinnie.com